Pfizer and AstraZeneca Debate: When “the Greater Good” Matters The business pages, and now the mainstream media, have been dominated over the last week with news of Pfizer’s proposed $106bn ...

The approval comes amid speculation that the big pharma company may switch its UK stock market listing to the US.

AstraZeneca (NASDAQ: AZN) and Pfizer (NYSE: PFE) -- along with one biotech stock, Exelixis (NASDAQ: EXEL). (AstraZeneca): ...

As of November 25, Pfizer's forward P/E ratio is just 8.8, considerably lower than Eli Lilly at 56.5 and AstraZeneca at 16.2. Pfizer also has a competitive price-to-book ratio of 1.54.

Detailed price information for Astrazeneca Plc ADR (AZN-Q) from The Globe and Mail including charting and trades.

Pfizer Inc. (NYSE:PFE) ranks among the best set-it-and-forget-it stocks to buy. On June 26, Pfizer Inc. (NYSE:PFE) declared ...

3SBio, which licensed Pfizer’s rights to SSGJ-707 for $1.25 billion upfront, presented mid-stage study data in a poster session that hinted at the drug’s promise in non-small cell lung cancer.

Pfizer’s Nurtec and AstraZeneca’s Breztri topped an analysis of the digital and omnichannel marketing strategies of the top pharma brands released Thursday morning. Trinity Life Sciences published its ...

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO By Annika Kim Constantino, CNBC and Ashley Capoot, CNBC • Published June 3, 2025 ...

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO By Annika Kim Constantino, CNBC and Ashley Capoot, CNBC • Published June 3, 2025 ...

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO By Annika Kim Constantino, CNBC and Ashley Capoot, CNBC • Published June 3, 2025 ...

Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO By Annika Kim Constantino, CNBC and Ashley Capoot, CNBC • Published June 3, 2025 ...